Caladrius Biosciences, Inc. CLBS Cash Flow

Caladrius biosciences, inc. (CLBS)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-3,986	-4,953	-4,897	-5,137	-4,365	-3,557	-3,549	-4,078	-4,984	-2,895	-3,547	38,465	-9,793	-6,089	-7,287	-7,884	-12,047	-33,228	-11,392	-17,158	-19,231	-11,690	-17,176	-12,769	-13,830	-12,718	-9,276	-8,625	-8,864	-15,343	-8,395	-33,422	-9,206	-28,854	-7,491	-10,537	-9,699
Income from discontinued operations
-	-	-	-	-	-	-	-	-	1,069	0	40,487	-3,157	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,007	152	-26,184	-1,227	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation
567	248	254	246	547	172	166	1,968	147	81	62	1,423	395	-501	1,392	31	851	1,181	436	4,416	3,715	2,268	3,288	1,759	3,893	1,426	2,098	1,095	2,218	1,241	1,916	1,078	2,476	2,101	1,507	4,638	2,018
Depreciation and amortization
15	15	15	18	17	17	39	82	87	87	90	94	98	99	98	-484	737	793	638	649	604	608	590	543	444	407	364	277	554	389	385	389	385	219	298	-1,280	2,203
Amortization of preferred stock discount and issuance cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	414	322	400	471	536	574	653	676
Changes in fair value of derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	90	-81	57	10	326	-64	24	87	435	1,365	558	-262
Change in acquisition-related contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	420	-5,350	550	-	690	210	190	-	0	0	0	-	-	-	-	-	-	-	-
(Gain) loss on disposal of assets
-	-	-	-	-	-	-	-	-	-	-	128	47	-	0	0	591	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion on marketable securities
-19	-	-39	-51	-82	-	-42	-73	-82	-	-179	-39	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Write off of acquired in-process research and development
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	223	0	927
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	83
Contributions paid with common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	607
Bad debt recovery
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1	-	3	0	1	-	225	7	0	-	-94	106	-340	147	-82	21	1
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-53	-	-46	3,703	-46	-	-47	-47	-47	-	-44	-447	0	-	-	-	-	-	-	-	-
Amortization/accretion on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	44	3	29	44	7	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49	-228
Prepaid and other current assets
-354	-268	-80	-113	223	-51	-126	-87	3	-296	-295	-336	-86	414	-465	-522	116	35	-539	-316	-52	-27	1,850	673	271	95	473	-1	192	182	-200	-42	238	126	411	-313	125
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-10	116	-112	51	46	270	1,001	-672	-1,144	1,021	-424	577	25	464	467	-191	-167	-557	587	97	426	-501	484	-362	822
Deferred costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,074	-436	375	-647	1,054	424	109	557	205	740	497	-1,509	428	664	-713	305	208	1,426	-1,589	-2,240	3,050
Unearned revenues
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,069	-152	855	-862	1,171	694	809	797	216	794	659	-1,453	346	546	-866	237	260	1,108	-1,313	1,726	-573
Other assets
-233	-232	-91	-90	-91	-109	-24	-68	-90	16	14	-159	-20	-30	-44	-65	-81	-232	-61	-53	61	-53	-666	53	53	204	-26	2	22	-2,601	7	0	180	-	-	-	-
Due to PCT
-	-	-	-	-	-	-	-	-	0	450	3,175	-1,943	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable, accrued liabilities and other liabilities
-1,443	-90	-39	-100	-1,635	81	-1,558	-2,706	-1,718	11,490	-2,943	-2,319	-560	64	-670	-2,412	-127	-3,067	1,024	3,328	-1,205	2,953	-868	43	-1,658	2,136	1,052	632	-905	965	-251	-606	1,570	-440	-1,007	3,433	-2,471
Net cash used in operating activities - continuing operations
-	-	-	-	-	-	-	-	-	-3,969	-6,329	-5,345	-4,593	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,364	-6,551	-6,229	-3,615	-	-	-	-
Net cash used in operating activities - discontinued operations
-	-	-	-	-	-	-	-	-	0	0	4,856	-5,494	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7,260	3,176	3,270	5,721	-	-	-	-
Net cash used in operating activities
-4,241	-4,220	-4,457	-4,719	-5,486	-3,042	-4,760	-5,885	-6,299	-3,969	-6,329	-488	-10,087	-3,375	-5,716	-6,547	-8,028	-8,727	-8,703	-7,586	-14,240	-10,903	-13,485	-11,252	-11,253	-7,363	-6,611	-5,990	-7,135	-9,624	-3,375	-2,958	2,106	-3,405	-4,256	-3,070	-10,195
Cash flows from investing activities:
Purchase of marketable securities
0	626	6,343	9,705	16,264	9,499	21,870	14,177	24,144	8,433	15,302	36,421	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sale of marketable securities
11,104	5,929	11,720	11,716	25,005	8,433	17,652	13,518	22,964	26,767	7,105	0	0	-	-	-	-	5,331	685	0	7,049	665	248	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Cash Acquired from Acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92	0	0	227
Change in restricted cash used as collateral for notes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3	0	-2,624	2,625
Acquisition of property and equipment
2	0	0	0	0	0	123	2	9	16	21	27	69	31	0	23	1,044	611	771	1,458	344	731	486	1,199	1,239	1,742	680	214	53	333	21	44	131	68	118	-319	707
Net cash (used in) provided by investing activities - continuing operations
-	-	-	-	-	-	-	-	-	18,235	-3,793	27,087	-69	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9,218	2,706	-44	-131	-	-	-	-
Net cash used in investing activities - discontinued operations
-	-	-	-	-	-	-	-	-	-0	0	-87	-101	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-441	-3,077	-2,162	21	-	-	-	-
Net cash provided by investing activities
11,102	5,303	5,377	2,011	8,741	-1,066	-4,291	1,839	-1,189	18,234	-3,793	27,000	-171	-533	-612	-658	-1,044	4,719	-3,154	-4,471	6,704	-7,189	-239	-2,068	-1,239	-1,742	-680	-214	-53	8,776	-371	-2,206	-110	1,073	3,288	-3,312	-3,104
Cash flows from financing activities:
Proceeds from exercise of options
-	-	-	-	-	0	13	302	40	-0	0	13	0	0	0	0	0	-	-	-	-	0	40	158	71	64	86	0	0	-	-	-	-	-	-	-	-
Tax withholding payments on net share settlement equity awards
148	0	0	0	130	0	0	358	45	0	0	334	23	72	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from issuance of common stock
0	275	0	38	1,000	33	710	288	0	23	2,400	37	3,241	-90	10,600	-45	1,096	334	0	28,724	7,411	5,435	1,125	4,518	5,630	37,218	7,269	11,517	2,730	4,268	2,209	2,260	7,691	-15	15,259	2,315	3,592
Repayment of long-term debt
-	-	-	-	-	-	-	-	-	-0	0	4,894	756	0	3,000	0	6,348	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of mortgage loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	3,131	52	52	51	57	49	43	55	47	40	52	40	45	62	2
Proceeds of bank loan
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,518
Proceeds from notes payable
-	-	-	-	-	-	-	-	-	0	0	0	400	434	0	0	368	0	-2	749	340	50	436	382	958	331	488	221	0	443	0	0	223	0	0	-7,099	7,249
Repayment of notes payable
-	-	-	-	-	0	23	69	67	200	242	328	193	314	225	154	335	50	308	335	259	359	294	280	163	170	236	15	81	252	28	93	66	47	-101	-2,042	2,277
Proceeds From Licensing Agreements, Milestone Payments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of debt to related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,000
Repayment of preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,135	866	816	575	-	-	-	-
Sale of ownership interest in subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,241	-1,012	0	0	-	-	-	-
Advance payment received from potential PCT sale
-	-	-	-	-	-	-	-	-	-	-	-	5,000	-	0	-4,400	19,400	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by (used in) financing activities - continuing operations
-	-	-	-	-	-	-	-	-	-177	2,157	-10,506	7,668	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,491	7,123	1,277	7,220	-	-	-	-
Net cash used in financing activities - discontinued operations
-	-	-	-	-	-	-	-	-	0	0	42	-116	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,171	-5,427	263	-34	-	-	-	-
Change in warrant liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	-	-	-	-	-	-	-	-
Net cash (used in) provided by financing activities
-148	275	0	38	870	33	700	163	-72	-177	2,157	-10,464	7,551	7	7,236	-520	14,180	283	-310	29,138	7,493	5,126	13,000	4,826	7,719	38,294	9,515	11,673	2,705	-1,680	1,695	1,541	7,185	3,552	7,666	1,769	7,080
Net increase in cash and cash equivalents
6,713	1,358	920	-2,670	4,125	-4,075	-8,351	-3,883	-7,560	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net (decrease) increase in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-	-	14,087	-7,965	16,047	-2,707	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impact of changes of foreign exchange rates
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	86	-30	11	-52	-188	164	51	18
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-7,726	5,107	-3,724	-12,168	17,080	-42	-12,967	-723	-8,494	-4,774	29,187	2,223	5,468	-4,483	-2,442	-2,081	-3,612	9,129	1,032	6,862	-4,561	-6,200
Supplemental Disclosure of Cash Flow Information:
Interest
-	-	-	-	-	0	0	2	3	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest
-	-	-	-	-	-	-	-	-	-	8	567	130	849	0	0	973	375	377	372	372	-126	163	103	93	71	76	30	95	116	411	623	620	284	-95	1,299	34
Proceeds from exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	0	346	98	1,275	901	2,020	0	105	678	5,925	0	0	-	-	-	-
Taxes
-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	258	1,029	525	286	-343	-171	338	1,295
Acquisition of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	894	389
Capitalized interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27	48	51	55	148	23	81	130
Common stock and warrants issued with the acquisition of PCT
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-666	0	17,866
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	308	191	525	725	825	1,175	783
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	45	26	104	126	147	166	308